Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645771 | 0.88 | DPP4 (0.57) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14646637 | 0.88 | DPP4 (0.57) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14646674 | 0.82 | FKBP1A (0.58) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14645717 | 0.82 | FKBP1A (0.58) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL11951498 | 0.82 | DPP4 (0.52) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14646652 | 0.81 | MEN1 (0.58) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL19468226 | 0.80 | DPP4 (0.49) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL29197797 | 0.80 | DPP4 (0.47) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL29197798 | 0.80 | DPP4 (0.47) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14646657 | 0.78 | DPP4 (0.53) | DPP4AGTR2HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| WO-2015179563-A2 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR IDENTIFICATION OF SERINE HYDROLASE TARGETS | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | HPN, BCHE, PRSS1 | DPP4 74/4885AGTR2 4590/4885HCRTR1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.